The effect of siRNA-Egr-1 and camptothecin on growth and chemosensitivity of breast cancer cell lines

Oncology Reports

Volumn 23, Issue 4, 2010, Pages 1159-1165

  Parra, Eduardo ^a   Ferreira, Jorge ^b  

^a UNIVERSIDAD DE TARAPACÁ   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Breast carcinoma; Camptothecin; Early growth response gene; Short RNA interference

Indexed keywords

CAMPTOTHECIN; EARLY GROWTH RESPONSE FACTOR 1; SMALL INTERFERING RNA;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL STRAIN MCF 7; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; DRUG EFFECT; DRUG MECHANISM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; BREAST NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EARLY GROWTH RESPONSE PROTEIN 1; FEMALE; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 77949474627     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000746     Document Type: Article

References (47)

1. Ausubel JH, Meyer PS, Iddo K and Wernick IK: Death and the human environment. Technol Soc 23: 131-146, 2001.
2. Wilke RA, Reif DM and Moore JH: Combinatorial pharmacogenetics. Nature 4: 911-918, 2005.
3. Agrawal N, Pallos J, Slepko N, et al: Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc Natl Acad Sci USA 102: 3777-3781, 2005.
4. Cao X, Koski RA, Gashler A, et al: Identification and characterization of the Egr-1 gene product, a DNA-binding zinc finger protein induced by differentiation and growth signal. Mol Cell Biol 10: 1931-1939, 1990.
5. Sukhatme VP, Cao X, Chang LC, et al: A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell 53: 37-43, 1988.
6. Sukhatme VP: The Egr transcription factor family: from signal transduction to kidney differentiation. Kidney Int 4: 550-553, 1992.
7. Virolle T, Krones-Herzig A, Baron V, Gregorio GG, Adamson ED and Mercola D: Egr1 promotes growth and survival of prostate cancer cells: identification of novel Egr1 target genes. Int J Biol Chem 278: 11802-11810, 2003.
8. Eid MA, Kumar MV, Iczkowski KA, Bostwick DG and Tindall DJ: Expression of early growth response genes in human prostate cancer. Cancer Res 58: 2461-2472, 1998.
9. Scharnhorst V, Menke AL and Attema J: EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity. Oncogene 19: 791-800, 2000.
10. Pignatelli M, Luna R, Perez A, Santos A and Castillo AP: The transcription factor early growth response factor-1 (EGR-1) promotes apoptosis of neuroblastoma cells. Biochem J 373: 739-746, 2003.
11. Houston P, Campbell CJ, Svaren J, Milbrandt J and Braddock M: The transcriptional corepressor NAB2 blocks Egr-1-mediated growth factor activation and agiogenesis. Biochem Biophys Res Commun 283: 480-486, 2001.
12. Collins S, Lutz MA, Zank PA, Anders R, Kersh G and Powell JD: Opposing regulation of T cell function by Egr-1/NAB2 and Egr-2/Egr-3. Eur J Immunol 38: 528-536, 2008.
13. Amorino G, Hamilton V, Valerie K, Dent P, Lammering G and Schmidt-Ullrich RK: Epidermal growth factor receptor dependence of radiation-induced transcription factor activation in human breast carcinoma cells. Mol Biol Cell 13: 2233-2244, 2002.
14. Eichelberger L, Koch M, Eble J, Ulbright T, Juliar B and Cheng L: Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. Mod Pathol 18: 886-890, 2005.
15. Dancey J and Eisenhauer EA: Current perspectives on camptothecins in cancer treatment. Br J Cancer 74: 327-338, 1996.
16. Kim YY, Park CK, Kim SK, et al: CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines. Oncol Rep 21: 1413-1419, 2009.
17. Han M, He CX, Fang QL, et al: A novel camptothecin derivative incorporated in nano-carrier induced distinguished improvement in solubility, stability and anti-tumor activity both in vitro and in vivo. Pharm Res 26: 926-935, 2008.
18. Slichenmyer WJ, Rowinsky EK, Donehower RC and Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271-291, 1993.
19. Pantazis P, Han Z, Chatterjee D and Wyche J: Water-insoluble camptothecin analogues as potential antiviral drugs. J Biomed Sci 6: 1-7, 1999.
20. Potmesil M, Vardeman D, Kozielski A, Mendoza J, Stehlin JS and Giovanella BC: Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res 55: 5637-5641, 1995.
21. Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 2446: 1046-1048, 1989.
22. Giovanella BC, Hinz H, Kozielski AJ, Stehlin JS, Silber R and Potmesil M: Complete growth inhibition ofhuman cancer xenografts in nude mice by treatment with 2O-(S)-camptothecin. Cancer Res 51: 3052-3055, 1991.
23. Tuschl T and Borkhardt A: Small interfering RNAs a revolutionary tool for the analysis of gene function and gene therapy. Mol Interv 2: 158-167, 2002.
24. Fire A, Xu S, Montgomery M, Kostas S, Driver S and Mello C: 'Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans'. Nature 391: 806-811, 1998.
25. Sioud M, Furset G and Cekaite L: Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAs. Biochem Biophys Res Commun 361: 122-126, 2007.
26. Elbashir SM, Lendeckel W and Tuschl T: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15: 188-200, 2001.
27. Sioud M: Does the understanding of immune activation by RNA predict the design of safe siRNA? Front Biosci 13: 4379-4392, 2008.
28. Hannon GJ and Rossi JJ: Unlocking the potential of the human genome with RNA interference. Nature 431: 371-378, 2004.
29. Stevenson M: Therapeutic potential of RNA interference. N Engl J Med 351: 1772-1777, 2004.
30. Parra E, Ortega A and Saenz L: Downregulation of Egr-1 by siRNA inhibits growth of human prostate carcinoma cell line PC-3. Oncol Rep 22: 1513-1518, 2009.
31. Persengiev SP, Zhu X and Green MR: Non-specific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNA). RNA 10: 12-18, 2004.
32. Sui G, Soohoo C, Affar E, Gay F, Forrester WC and Shi Y: A DNA vector based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 99: 5515-5520, 2002.
33. Inostroza J, Saenz L, Calaf G, Cabello G and Parra E: Role of the phosphatase PP4 in the activation of JNK-1 in prostate carcinoma cell lines PC-3 and LNCaP resulting in increased AP-1 and EGR-1 activity. Biol Res 38: 163-178, 2005.
34. Huang RP, Fan Y, de Belle I, Niemeyer C, Gottardis MM, Mercola D and Adamson ED: Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer 72: 102-109, 1997.
35. Carbonero G and Supko JG: Cancer treatment using viruses and camptothecins. Clin Cancer Res 8: 641-661, 2002.
36. Pizzolato JF and Saltz LB: The camptothecins. Lancet 361: 2235-2242, 2003.
37. Ruo-Pan Huang RP, Fan Y, Peng A, Zeng ZL, Reed JC and Adamson ED: Suppression of human fibrosarcoma cell growth by transcription factor, Egr-1, involves down-regulation of Bcl-2. Int J Cancer 77: 880-886, 1995.
38. Huang RP, Fan Y, Ni Z, Mercola D and Adamson ED: Reciprocal modulation between Sp and Egr-1. J Cell Biochem 66: 489-499, 1997.
39. Calogero A, Lombari V, Porcellini A, et al: Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma. Cancer Cell Int 4: 1-8, 2004.
40. Hao MW, Liang YR, Liu YF, Liu L, Wu MY and Yang HX: Transcription factor EGR-1 inhibits growth of hepatocellular carcinoma and esophageal carcinoma cell lines. World J Gastroenterol 8: 203-207, 2002.
41. Wu MY, Zhuang CX, Yang HX and Liang YR: Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors. World J Gastroenterol 10: 476-480, 2004.
42. Shozu M, Murakami K, Segawa T, et al: Decreased expression of early growth response-1 and its role in uterine leiomyoma growth. Cancer Res 64: 4677-4684, 2004.
43. Baron V, Adamson ED, Calogero A, Ragona G and Mercola D: The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGF beta 1, PTEN, p53, and fibronectin. Cancer Gene Ther 13: 11-18, 2006.
44. Liu C, Yao J, Mercola D and Adamson E: The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J Biol Chem 275: 20315-20323, 2000.
45. Shuangli N, Fuessel S, Kotzsch M, et al: siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 25: 1065-1071, 2004.
46. Kaufmann K and Thiel G: Epidermal growth factor and platelet-derived growth factor induce expression of Egr-1, a zinc finger transcription factor, in human malignant glioma cells. J Neurol Sci 189: 83-91, 2001.
47. Reynolds A, Leake D and Boese Q: Rational siRNA design for RNA interference. Nat Biotechnol 22: 326-330, 2004.